Background: Several phase-III studies have shown improvements in terms of progression-
free survival (PFS) with bevacizumab when added to chemotherapy in advanced breast …

Background. Hypertension is a common toxicity of bevacizumab, but the frequency of
assessment of blood pressure and standardized grading remain to be defined. This study …

Background Hypertension is associated with the use of bevacizumab, an angiogenesis
inhibitor widely used in cancer therapy. Currently, the risk of severe hypertension associated …

Background Although the addition of bevacizumab significantly improves the efficacy of
chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the …

3039 Background: HTN is associated with anti-VEGF treatment (Tx), but this association has
not been well studied. To assess the prognostic and predictive importance of BV-related …

Methods Patients from 8 centres were included between 2009 and 2011 with a follow-up of
1 year. They were naive of any previous anti-VEGF treatment and planned to be started on …

found that the occurrence of hypertension [grade‡ 3 according to the National Cancer
Institute—Common Toxicity Criteria (NCI-CTC)[13]] was associated with a higher response …

Bevacizumab (BV), an inhibitor of vascular endothelial growth factor, is used in combination
with paclitaxel (PTX) to treat advanced breast cancer. Hypertension and proteinuria are …

Background There are limited data on treatment outcomes in the growing population of
elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain …

Background. Hypertension is associated with antivascular endothelial growth factor
treatment, but the clinical implications of hypertension are uncertain. To assess the …